Advertisement


Louis B. Nabors, MD, on NCCN Clinical Practice Guidelines in Oncology Updates for CNS Cancers in Adults

NCCN 2023 Annual Conference

Advertisement

Louis B. Nabors, MD, of the O’Neal Comprehensive Cancer Center at UAB, discusses the three subtypes of adult gliomas classified by the World Health Organization, treatments influenced by IDH mutation status, the roles of radiotherapy and chemotherapy, molecular testing, and pseudoprogression and RANO (response assessment in neuro-oncology) criteria.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Louis B. Nabors: The NCCN CNS tumor Committee had a productive year and update was reported at the meeting. There are several big changes that you'll kind of notice and most of these revolve around the sections we call GLIO, G-L-I-O. And so you're going to see some changes that are reflective of a change in the WHO'S classification of glioma. This occurred in 2021 and over the past two years, we've been working to incorporate the classification changes into the guidelines. Much of this will be reflective in some of the titles. Example is GLIO1, we are no longer using the term low grade. We're trying to avoid that, GLIO1, which are what we now call circumscribed gliomas, compromised pilocytic astrocytomas, subependymal giant cell astrocytomas, and pleomorphic xanthoastrocytomas, which can be Grade 2, but these are more circumscribed. GLIO2 is oligodendroglioma. What you'll notice for GLIO2 and 2, which are oligodendroglioma and astrocytoma, the title includes a molecular classification, IDH mutation. In addition, on astrocytoma, which is GLIO3, you will notice a new astrocytoma which is called astrocytoma WHO 4, IDH-mutated. These previously were included in glioblastoma, but if they are IDH-mutated, they will fall under GLIO3. In addition, we've inserted a new category, which is GLIO9 for the H3 mutated glioma. These include the H3K27M and the H3G34. The classification in the pages, now we've moved a section that we called the Principles of Brain and Spine Tumor Systemic Therapy, which was formally called Brain D, we've moved that to follow the algorithm pages, so now the systemic treatment options will follow the page and the algorithm for where those systemic therapies are appropriate. And these are now using the NCCN preference stratification, which are preferred, other recommended, or useful in certain circumstances. Now we have expanded BRAIN F to include additional information related to molecular testing. All glioma need to have IDH status. They need to have MGMT status, and if there's a question that they could potentially be a glioblastoma, we would highly recommend the inclusion of ATRX TERT EGF receptor status and CDK2NANB. Last couple of points, be alert to the need for treatment response using the RANO Criteria. This is the response assessment in neuro-oncology. It depends on three factors. One is the imaging. The imaging is both the post contrast and the flare. In addition, how somebody is doing clinically and what their dose of steroids is. Be alert to the phenomena of what we call pseudoprogression. This is a change on the MRI which is related to the treatment and not related to the disease. This is very prominent at the first MRI post chemoradiation for glioblastoma or astrocytoma Grade 4, and you should wait till three months post-radiation unless very specific criteria such as enhancement or disease changes outside of the field of radiation are present.

Related Videos

Gastroesophageal Cancer
Immunotherapy

Michael K. Gibson, MD, PhD, on Metastatic Esophageal Squamous Cell Carcinoma: New First-Line Systemic Treatment Options

Michael K. Gibson, MD, PhD, of Vanderbilt-Ingram Cancer Center, discusses the importance of developing additional treatment strategies for patients with advanced or metastatic esophageal squamous cell carcinoma and describes the role of immune checkpoint inhibitors. Dr. Gibson also reviews the available evidence on the use of nivolumab in this patient population.

Solid Tumors
Bladder Cancer

Arlene O. Siefker-Radtke, MD, on Urothelial Cancer: Emerging Therapies

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, provides an overview of the emerging treatments for urothelial cancer, including several new agents in the antibody-drug conjugate and tyrosine kinase inhibitor classes. She describes the clinical activity and toxicities of enfortumab vedotin-ejfv, erdafitinib, and sacituzumab govitecan-hziy.

Issues in Oncology

Mandi L. Pratt-Chapman, PhD, on Oncology Care in the LGBTQI+ Community: Best Practices for Addressing Health Needs

Mandi L. Pratt-Chapman, PhD, of the George Washington University Cancer Center, discusses the specific health-care needs for cancer screening, treatment, and survivorship among members of the LGBTQI+ community. Because clinical practices and research studies do not routinely collect sexual orientation and gender identity data, there is insufficient evidence to guide clinical care decision-making, Dr. Pratt-Chapman says.

Natalie Moryl, MD, on Managing Pain in Patients With Cancer

Natalie Moryl, MD, of Memorial Sloan Kettering Cancer Center, discusses severe cancer pain, a medical emergency that should be addressed with immediate intervention. The treatment plan, Dr. Moryl says, should include making a pain diagnosis; addressing reversible causes of pain such as spinal cord compression, fracture, or obstruction; selecting, titrating, and rotating opioids and co-analgesics; and routine screening for risks of opioid use disorder and mental health comorbidities.

Immunotherapy

Jordan McPherson, PharmD, MS, BCOP, on Managing Immunotherapy-Related Toxicities

Jordan McPherson, PharmD, MS, BCOP, of the Huntsman Cancer Institute at the University of Utah, summarizes a case-based panel discussion on best practices in caring for patients with immune-related adverse events. He focuses on pneumonitis, which can occur with immune checkpoint inhibitor therapy, detailing factors such as comorbidities, infectious etiology, and disease progression; the need to consider myositis and myasthenia gravis in patients who develop immune-related myocarditis; and oral toxicities including mucositis and sicca syndrome.

Advertisement

Advertisement




Advertisement